U.S. Markets close in 23 mins.

Elite Pharmaceuticals, Inc. (ELTP)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1170.000 (0.000%)
As of 2:51PM EDT. Market open.
People also watch
AMBSONCSIGXTRNNMSTX
Full screen
Previous Close0.117
Open0.120
Bid0.000 x
Ask0.000 x
Day's Range0.115 - 0.120
52 Week Range0.100 - 0.250
Volume689,837
Avg. Volume1,469,139
Market Cap90.74M
Beta0.29
PE Ratio (TTM)-16.71
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Elite Pharmaceuticals, Inc. :ELTP-US: Earnings Analysis: Q4, 2017 By the Numbers : June 16, 2017
    Capital Cubelast month

    Elite Pharmaceuticals, Inc. :ELTP-US: Earnings Analysis: Q4, 2017 By the Numbers : June 16, 2017

    Categories: Yahoo FinanceGet free summary analysis Elite Pharmaceuticals, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Elite Pharmaceuticals, Inc. – Mylan N.V., Acura Pharmaceuticals, Inc., Cambrex Corporation, Aceto Corporation, Nektar Therapeutics, Pfizer Inc. and Albany Molecular Research, Inc. (MYL-US, ACUR-US, CBM-US, ACET-US, NKTR-US, PFE-US ... Read more (Read more...)

  • Elite Pharmaceuticals, Inc. :ELTP-US: Earnings Analysis: Q3, 2017 By the Numbers : March 15, 2017
    Capital Cube4 months ago

    Elite Pharmaceuticals, Inc. :ELTP-US: Earnings Analysis: Q3, 2017 By the Numbers : March 15, 2017

    Categories: Yahoo Finance Get free summary analysis Elite Pharmaceuticals, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Elite Pharmaceuticals, Inc. – Mylan N.V., Cambrex Corporation, Aceto Corporation, Nektar Therapeutics, Pfizer Inc., Albany Molecular Research, Inc. and Akorn, Inc. (MYL-US, CBM-US, ACET-US, NKTR-US, PFE-US, AMRI-US and ... Read more (Read more...)

  • TheStreet.com11 months ago

    Trending Tickers: CZR, APO, MCUR, KS, ELTP

    Caesars shares sink after a judge ruled that it would not be shielded from $11 billion in bondholder lawsuits.